The aims of the present trial were to study the individual responsiveness to growth hormone (GH) treatment, in terms of body composition, and to search for possible predictors of the response in GH-deficient adults. Sixty-eight patients (44 men, 24 women) with a mean age (± SEM) of 44.3 ±1.2 years and verified GH deficiency participated in a 12-month treatment trial with GH. Recombinant human GH was administered subcutaneously at a target dose of 12 ug/kg/day. GH-binding protein (GHBP) was measured by a ligand-mediated immunofunctional assay and serum insulin-like growth factor I (IGF-I) was determined by radioimmunoassay after acid-ethanol extraction, using a truncated IGF-I analogue as radioligand. Lean body mass and body fat were determined by dual-energy X-ray absorptiometry, and total body water by bioelectrical impedance analysis. After 12 months of GH treat-ment, serum IGF-I, lean body mass and total body water increased (P < 0.001), while body fat (P < 0.001) and serum GHBP (P< 0.05) decreased. The individual changes in body fat ranged from -12.5 to +4.3 kg, and for lean body mass from -4.5 to +10.1 kg. Age (P < 0.05) and baseline GHBP level (P < 0.01) were inversely correlated with the increase in lean body mass, and baseline GHBP was inversely correlated with the increase in lean/fat ratio (P< 0.001). The GH-induced increment in IGF-I and total body water was greater in men than in women (P < 0.01), while the decrease in body fat was similar in men and women. This trial demonstrates the variability in responsiveness to GH administration in GH-deficient adults. The best response to GH was obtained in younger patients with low GHBP levels. Furthermore, men responded better than women.
|Fræðitímarit||Endocrinology and Metabolism, Supplement|
|Númer tölublaðs||SUPPL. A|
|Útgáfustaða||Útgefið - 1996|